SEARCH

SEARCH BY CITATION

References

  • 1
    Wilcox MH, Freeman J. Epidemic Clostridium difficile. N Engl J Med 2006; 354: 11991203.
  • 2
    Kuijper EJ, Dissel JT, Wilcox MH. Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis 2007; 20: 376383.
  • 3
    Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 15911597.
  • 4
    Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466472.
  • 5
    Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987–2001. J Infect Dis 2004; 189: 15851589.
  • 6
    McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 24332441.
  • 7
    Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366: 10791084.
  • 8
    Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 24422449.
  • 9
    Kuijper EJ, van den Berg RJ, Debast S et al. Clostridium difficile ribotype  027, toxinotype  III, the Netherlands. Emerg Infect Dis 2006; 12: 827830.
  • 10
    Kuijper EJ, Debast SB, Van Kregten E, Vaessen N, Notermans DW, van den Broek PJ. Clostridium difficile ribotype  027, toxinotype  III in the Netherlands. Ned Tijdschr Geneeskd 2005; 149: 20872089.
  • 11
    Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper EJ. Characteristics and incidence of Clostridium difficile-associated disease in the Netherlands. Clin Microbiol Infect 2007; 13: 10581064.
  • 12
    Goorhuis A, Van der Kooi T, Vaessen N et al. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype  027/toxinotype  III in the Netherlands. Clin Infect Dis 2007; 45: 695703.
  • 13
    Dubberke ER, Reske KA, McDonald LC, Fraser VJ. Evaluation of ‘CDAD pressure’ as a risk factor for Clostridium difficile-associated disease. Arch Intern Med 2007; 167: 10921097.
  • 14
    Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007; 15: 45.
  • 15
    Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40: 115.
  • 16
    Samore MH. Epidemiology of nosocomial Clostridium difficile diarrhoea. J Hosp Infect 1999; 43 (suppl): S183S190.
  • 17
    Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA. Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 2005; 26: 680684.
  • 18
    Bliss DZ, Johnson S, Savik K et al. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feedings. Ann Intern Med 1998; 129: 10121019.
  • 19
    Kyne L, Sougioultzis S, McFarland LV, Kelly CP. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 2002; 23: 653659.
  • 20
    Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54: 243245.
  • 21
    Dial S, Alrasadi K, Manoukian C, Huang A. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171: 3338.
  • 22
    Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 29892995.
  • 23
    Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 12541260.
  • 24
    Muto CA, Pokrywka M, Shutt K et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273280.
  • 25
    Gaynes R, Rimland D, Killum E et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 2004; 38: 640645.
  • 26
    Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 1998; 36: 22402247.
  • 27
    Stubbs SL, Brazier J, O’Neill GL, Duerden BI. PCR targeted to the 16S–23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999; 37: 461463.
  • 28
    WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, 5th edn. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2002.
  • 29
    Hennekens CH. Measures of disease frequency and association. In: Hennekens CH, Buring JE, Mayrent SL, eds. Epidemiology in medicine. Boston: Little, Brown and Company, 1987; 9097.
  • 30
    Owens RC, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46: S19S31.
  • 31
    Muto CA, Blank MK, Marsh JW et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive ‘bundle’ approach. Clin Infect Dis 2007; 45: 12661273.
  • 32
    Yip C, Loeb M, Salama S, Moss L, Olde J. Quinolone use as a risk factor for nosocomial Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol 2001; 22: 572575.
  • 33
    Bates CJ, Wilcox MH, Spencer RC, Harris DM. Ciprofloxacin and Clostridium difficile infection. Lancet 1990; 336: 1193.
  • 34
    Cain DB, O’Connor ME. Pseudomembranous colitis associated with ciprofloxacin. Lancet 1990; 336: 946.
  • 35
    McFarland LV, Bauwens JE, Melcher SA, Surawicz CM, Greenberg RN, Elmer GW. Ciprofloxacin-associated Clostridium difficile disease. Lancet 1995; 346: 977978.
  • 36
    Ozawa TT, Valadez T. Clostridium difficile infection associated with levofloxacin treatment. J Tenn Med Assoc 2002; 95: 113115.
  • 37
    Stein GE, Goldstein EJ. Fluoroquinolones and anaerobes. Clin Infect Dis 2006; 42: 15981607.
  • 38
    Drudy D, Kyne L, O’Mahony R, Fanning S. GyrA mutations in fluoroquinolone-resistant Clostridium difficile PCR-027. Emerg Infect Dis 2007; 13: 504505.
  • 39
    Vonberg RP, Kuijper EJ, Wilcox MH et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect Dis 2008; 14 (suppl 5): 220.
  • 40
    Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007; 45: S112S121.